tiprankstipranks
ImmuPharma plc (GB:IMM)
:IMM
UK Market

ImmuPharma (IMM) Income Statement

Compare
19 Followers

ImmuPharma Income Statement

Last quarter (Q2 2024), ImmuPharma's total revenue was £0.00, a decrease of -100.00% from the same quarter last year. In Q2, ImmuPharma's net income was £-193.93K. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
£ 0.00£ 0.00£ 118.35K£ 126.67K£ 77.92K
Gross Profit
£ -37.61K£ -117.56K£ 118.35K£ 126.67K£ 77.92K
Operating Expenses
£ 3.06M£ 3.03M£ 5.28M£ 5.72M£ 6.36M
Depreciation and Amortization
£ 37.61K£ 117.56K£ 114.12K£ 170.96K£ 90.32K
EBITDA
£ -3.03M£ -2.91M£ -8.70M£ -6.84M£ -6.65M
Operating Income
£ -3.06M£ -3.03M£ -6.59M£ -5.59M£ -6.28M
Other Income/Expenses
£ -355.89K£ -1.43M£ -2.35M£ -1.66M£ -462.72K
Pretax Income
£ -3.42M£ -4.46M£ -8.94M£ -7.25M£ -6.74M
Net Income
£ -2.92M£ -3.81M£ -8.17M£ -6.86M£ -6.12M
Per Share Metrics
£ ―£ ―£ ―£ ―£ ―
Basic EPS
£ -0.01£ -0.01£ -0.03£ -0.03£ -0.04
Diluted EPS
£ -0.01£ -0.01£ -0.03£ -0.03£ -0.04
Weighted Average Shares Outstanding
360.72M 302.91M 251.16M 200.00M 153.45M
Weighted Average Shares Outstanding (Diluted)
362.00M 302.91M 251.16M 200.18M 153.45M
Currency in GBP

ImmuPharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis